Resistance Platform Spanish AIDS R. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.

Betancor G, Garriga C, Puertas MC, Nevot M, Anta L, Blanco JL, Pérez-Elias MJ, De Mendoza, C, Martínez MA, Martínez-Picado J, Menendez-Arias L.

Retrovirology. 2012; 9: -0. FI: 6.470 (Q1).

CoRIS. Definition of Advanced Age in HIV Infection: Looking for an Age Cut-Off.

Blanco JR, Jarrin I, Vallejo M, Berenguer J, Solera C, Rubio R, Pulido F, Asensi V, Del Amo J, Moreno S.

Aids Res. Hum. Retrovir. 2012; 28: 800-806. FI: 2.246 (Q3).

CoRIS Cohort. Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms.

Hernando V, Sobrino-Vegas P, Burriel MC, Berenguer J, Navarro G, Santos I, Reparaz J, Martinez MA, Antela A, Gutiérrez F, Del Amo J.

Aids. 2012; 26: 1829-1834. FI: 6.245 (Q1).

CoRIS. Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care.

Sobrino-Vegas P, Rodríguez-Urrego J, Berenguer J, Caro-Murillo AM, Blanco JR, Viciana P, Moreno S, Bernardino I, Del Amo J.

Antivir. Ther. 2012; 17: 1-8. FI: 3.161 (Q2).

STOPAR Study Team. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.

Imaz A, Olmo M, Penaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Niubo J, Curto J, Vilallonga C, Masia M, López-Aldeguer J, Iribarren JA, Podzamczer D.

Antivir. Ther. 2012; 17: 577-583. FI: 3.161 (Q2).

COINS Study Team. Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.

Pineda JA, Neukam K, Mallolas J, López-Cortés LF, Carton JA, Domingo P, Moreno S, Iribarren, JA, Clotet B, Crespo M, De Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Macías J.

J. Infect. 2012; 64: 204-211. FI: 4.126 (Q1).

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients.

Macías J, Berenguer J, Japón MA, Giron-González JA, Rivero A, López-Cortés LF, Moreno A, Márquez M, Iribarren JA, Ortega E, Miralles P, Merchante N, Pineda JA.

Hepatology. 2012; 56: 1261-1270. FI: 11.665 (Q1).

Antiretroviral Therapy Cohort. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.

May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiebaut R, Gill M J, Kirk O, Van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, Monforte AD'Arminio, Vehreschild JJ, Sterne JAC.

Int. J. Epidemiol. 2012; 41: 1807-1820. FI: 6.414 (Q1).

HIV-CAUSAL Collaboration. Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries.

Del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrin I, Phillips A, Lodi S, Van Sighem, A, De Wolf F, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernan MA.

Clin. Infect. Dis. 2012; 54: 1364-1372. FI: 9.154 (Q1).

COINS Study Team. Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients.

Macías J, Neukam K, Mellolas J, López-Cortes LF, Carton JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, De Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Pineda JA.

HIV Clin. Trials. 2012; 13: 61-69. FI: 1.638 (Q3).

Holguin, Africa, Cohort Spanish Aids Res Network Co. Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-Naive HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses.

Yebra G, De Mulder M, Martín L, Rodríguez C, Labarga P, Viciana I, Berenguer J, Alemán MR, Pineda JA, García F.

J. Clin. Microbiol. 2012; 50: 407-413. FI: 4.153 (Q1).

Call Conference Grp. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.

Santos JR, Llibre JM, Imaz A, Domingo P, Iribarren JA, Marino A, Miralles C, Galindo MJ, Ornelas A, Moreno S, Schapiro JM, Clotet B.

J. Antimicrob. Chemother. 2012; 67: 1462-1469. FI: 5.068 (Q1).

GESIDA 6409 Study Grp. Outcomes in HIV-infected patients admitted due to pandemic influenza.

Lopez-Aldeguer J, Iribarren JA, Valencia E, Barquilla E, Knobel H, Santos J, Lozano F.

Enferm. Infec. Microbiol. Clin. 2012; 30: 608-612. FI: 1.491 (Q3).

SinRES Team. Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations.

Garrido C, De Mendoza C, Álvarez E, García F, Morello J, García S, Ribera E, Rodríguez-Novoa S, Gutiérrez F, Soriano V.

Aids Res. Hum. Retrovir. 2012; 28: 156-164. FI: 2.246 (Q3).